• Nilay D Solanki Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charusat University, Changa, Gujarat
  • Alkesh Patel CBCC Global research India, Ahmedabad.
  • Leena Patel Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charusat University, Changa, Gujarat


Objective: The objective of this study was to evaluate the cytotoxic potential of A3AR agonist (ABMECA) against human lung cancer cell line A549 by using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay.

Methods: Adenocarcinoma cell line A549 was used to assess MTT based cells viability. In vitro cytotoxic activity was evaluated for 3 different concentration of doxorubicin and A3AR by MTT cytotoxicity assay. Cytotoxicity assay carried out for 3 consecutive days that involves culturing cells into Dulbecco’s MEM medium modified with 10% FBS for 24 h then treatment with different dose of standard and test drug with incubation period of 24 h followed by treatment with MTT for estimation of cytotoxicity and finally, optical density (OD) was measured at 570-630 nm.

Results: Different concentration of doxorubicin (1, 5, 10 µM) and ABMECA (10-6M, 10-5M and 10-4M) shown dose-dependent cytotoxicity. There was a significant decrease (p<0.05) in cell viability in both doxorubicin and ABMECA concentration in a dose-dependent manner. This study may guide further for in vivo evaluation of test drug in the lung cancer model.

Conclusion: A3 Adenosine Receptor agonist could be potential moiety for the treatment of lung cancer and it would require in vivo study for further research.

Keywords: A549 cell line, Adenosine, Doxorubicin, MTT assay, Lung cancer


Download data is not yet available.


1. Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11:GLOBOCAN 2012 v1.0;2012. Available from: [Last accessed on 21 Jun 2018]
2. NICPR. Cancer Statistics; 2017. Available from: [Last accessed on 21 Jun 2018].
3. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, et al. A2B and A3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (New York, NY) 2009;11:1064-73.
4. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, et al. A glance at adenosine receptors: a novel target for antitumor therapy. Pharmacol Ther 2003;100:31-48.
5. Fishman P, Bar Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, et al. Adenosine receptors and cancer. Hand Exp Pharmacol 2009;193:399-441.
6. Sacchetto V. The a3 adenosine receptor: a link between inflammation and cancer. Pubblicazionidello IUSS 2010;3:1-149.
7. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156:3435-42.
8. [Last accessed on 05 Apr 2018]
9. Hwa Yeon Jo. The unreliability of MTT assay in the cytotoxic test of primary cultured glioblastoma cells. Exp Neurobiol 2015;24:235-45.
10. Ashutosh Bahuguna, Imran Khan, Vivek K Bajpai, Sun Chul Kang. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh J Pharmacol 2017;12:115-8.
11. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 1991;1:2515–20.
12. Wang P, Henning SM, Heber D. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010;5:e10202.
13. Kenneth A Jacobson, Zhan Guo Gao. Adenosine receptors as therapeutic targets. Nat Rev Drug Discovery 2006;5:247–64
14. Habeela J, Mohan MR. In vitro cytotoxic and apoptosis study of chemical constituents from clerodendrum phlomidis leaf on mcf-7 and a549 cancer cell lines. Asian J Pharm Clin Res 2018;11:299-304.
128 Views | 35 Downloads
How to Cite
Solanki, N. D., A. Patel, and L. Patel. “IN VITRO EVALUATION OF ANTI-CANCER POTENTIAL OF A3 ADENOSINE RECEPTOR AGONIST ON A549 HUMAN LUNG CANCER CELL LINE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 11, no. 6, Apr. 2019, pp. 106-8, doi:10.22159/ijpps.2019v11i6.30863.
Short Communication(s)